Zoekresultaten - 5 results
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Wilkinson, Robert J; McShane, Helen; MVA85A 030 trial investigators Source: Lancet Respir Med, Volume 3, Issue 3, p.190-200 (2015) Keywords: ADOLESCENT Adult Antibodies, Bacterial Antigens, CD CD4 Lymphocyte ...
Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 14581
effects environment environmental risk assessment Functional gene gene therapy gene transfer genomic Genomics Hand Human Humans interaction interactions Interference IS IT lifetime MVA neurological Neurons ...
Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
Animals Clinical Trials as Topic Genetic Therapy Genetic Vectors Hazardous Substances Humans Risk Assessment Vaccination vaccinia virus Viral Vaccines Abstract: The modified vaccinia virus Ankara (MVA ...
Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.
Abstract: The modified vaccinia virus Ankara (MVA) strain is a highly attenuated strain of vaccinia virus that has been demonstrated to be safe for humans. MVA is widely considered as the vaccinia virus ...
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
infected mice: 17 weeks in both experiments). On the other hand, boosting of BCG by subsequent Ag85A DNA in saline or vaxfectin–or recombinant 85A protein or MVA-85A for that matter–did not augment the ...